Added to YB: 2024-01-25
Pitch date: 2024-01-24
SGMT [bullish]
Sagimet Biosciences Inc.
-55.95%
current return
Author Info
No bio for this author
Company Info
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States.
Market Cap
$472.4M
Pitch Price
$15.89
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.58
P/E
-5.67
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Sagimet: Additional Upside Possible After Latest NASH Data Release
SGMT: Denifanstat met Phase 2b NASH F2-F3 endpoints, Phase 3 possible in H2 '24 after FDA mtg. Phase 1 liver impairment data due early '24. Partner Ascletis: Ph3 glioblastoma enrolled, +Ph2 acne data. $96M IPO + Series A funded >12mo. Risks: FDA, trial results, FASN strategy.
Read full article (6 min)